TOP CORPORATE NEWS - 27 APR 2016

Alembic Pharma Q4: Cons Net Profit +29.6% at Rs91.2 Cr

Alembic Pharma Q4: Cons Net Profit +29.6% At Rs.91.2 Cr Vs Rs.70.3 Cr (YoY)

Cons Total Income +24.6% At Rs.626.6 Cr Vs Rs.503 Cr (YoY)

Cons EBITDA At Rs.143.3 Cr Vs Rs.98 Cr (YoY)

Cons EBITDA +46.3% At Rs.143.3 Cr Vs Rs.98 Cr (YoY)

India Generic Biz Revenue -46% At 17.4 Cr Vs Rs.32.1 Cr (YoY)

India Branded Biz Revenue +12% At 259.6 Cr Vs Rs.232.1 Cr (YoY)

Intl Biz Revenue +20% At 190.2 Cr Vs Rs.158.3 Cr (YoY)

Axis Bank drops post Q4FY16 results

Shares of Axis Bank dropped 3.4% to Rs464 on NSE post Q4FY16 result update where business growth remained healthy; Asset quality stable; PT revised to Rs590

NII up 19.8%; Margins expand: Axis bank reported a strong 19.8% growth in Net interest for Q4FY16 owing to 20.5% jump in the advances and expansion in Net Interest Margins (up 16 BPS Yo and 18 BPS QoQ). Non-interest income growth was flat as treasury profit declined by 65.4% YoY, however retail fee income showed a growth of 15.1% YoY. Provisions for Q4FY16 surged by 64.6% YoY owing to Rs300 crore contingent provisions made during the quarter.

Yes Bank reports robust operating performance; Asset quality deteriorates

Yes Bank has announced the following audited Q4 & FY16 results for the quarter & year ended March 31, 2016:

Standalone

The Bank has posted a net profit of Rs702.11 crore Vs Rs550.99 crore (YoY).

Total Income increased to Rs4331.11 crore Vs Rs3678.83 crore (YoY).

M&M launches bigger variant of Bolero pick-up truck

M&M launches bigger variant of the Bolero pick-up truck; to further consolidate leadership in pick up category

M&M launched the new “Big Bolero” pick-up truck in two variants on with 1,250 Kg payload and the other with 1,500 Kg payload.

The pick-up is powered by the proven MDI Turbo charged engine. The vehicle is priced at Rs6.15 lakh (BS3 ex showroom Pune) and Rs6.3 lakh (BS4 ex-showroom Pune).

Aurobindo Pharma receives USFDA approval for Oxymorphone Tablets

Aurobindo Pharma receives USFDA Approval for Oxymorphone Hydrochloride Tablets – Positive for Aurobindo.

Aurobindo gets final approval from USFDA to manufacture and market Oxymorphone Hydrochloride Tablets, used to help relieve moderate to severe acute pain where the use of an opioid is appropriate.

The approved product has an estimated market size of US$ 55.5 million for the twelve months ending February 2016 according to IMS.

                              

Get real time advice for Intraday Trading Tips , Share Market Live  , Intraday Equity Tips , Stock Trading tips , Free Intraday Tips , Best Accurate Stock Tips , NSE Stock market Tips and all Maket Updates .